Pinobio Reveals PBX-7 Nonclinical Data at World ADC

Trastuzumab Deruxtecan's 'DXd'
Shows "Equivalent or Superior Efficacy" Compared

Pinobio logo (left) and 'World ADC 2023' logo [Photo by Pinobio]

Pinobio announced on the 16th that it had unveiled for the first time the preclinical experimental data of its self-developed antibody-drug conjugate (ADC) drug (payload) ‘PBX-7 series’ at ‘World ADC 2023’ held in London, UK on the 14th (local time).

The presentation materials included ▲cell line experimental results of the PBX-7 series ▲comparative experiments with ‘DXd,’ the payload of trastuzumab deruxtecan ▲preclinical experimental results of a HER2-targeting ADC candidate synthesized by combining the PBX-7 series with the antibody trastuzumab.

The PBX-7 series developed by Pinobio is a camptothecin-class drug similar to DXd. It has a dual mechanism that inhibits enzymes involved in cancer cell proliferation while also suppressing proteins that prevent cancer cell death. In vitro experiments targeting various cancer cell lines such as triple-negative breast cancer (TNBC) and head and neck cancer showed equal or superior efficacy compared to DXd. In cell line and animal model experiments conducted after synthesizing it with trastuzumab to create a HER2-targeting ADC candidate, it demonstrated superior anticancer effects compared to trastuzumab deruxtecan, an ADC with the same target.

As the name suggests, ADCs are pharmaceuticals that conjugate antibodies and drugs. By linking antibodies that bind to cancer antigens with cytotoxic drugs called payloads via linkers, they can effectively deliver toxins specifically to cancer cells like missiles, making them a next-generation anticancer technology attracting attention.

Jung Doo-young, CEO of Pinobio, said, “The PBX-7 series drug is a compound that can overcome the limitations of existing ADC payloads with excellent efficacy and low toxicity. We will successfully carry out the ongoing non-GLP primate toxicity evaluation and further advance the competitiveness of Pinobio’s ADC platform PINOT-ADC.”

This content was produced with the assistance of AI translation services.